Blood-clot death ‘likely’ linked to AstraZeneca COVID vaccine The TGA has confirmed the recent death of a 48-year-old NSW woman was likely linked to the vaccine: ‘A causative link to vaccination should be assumed at this time’.
‘Seeds of fear and mayhem’: Concerns media hindering vaccine rollout Journalists have a responsibility to not undermine the science and contribute to issues of vaccine hesitancy, according to the RACGP President.
Department of Health eyes vaccine MBS ‘recalibration’ Medicare rebates were one of several issues raised by GPs at a recent primary care webinar on the rollout of the AstraZeneca COVID vaccine.
Improving COVID vaccine rollout top of RACGP advocacy list Dr Michael Wright details the college’s recent behind-the-scenes advocacy work.
Blood clots, supply issues, new technologies: Does Australia need another COVID vaccine option? After delays with Novavax, advising against AstraZeneca for under-50s, and ruling out Johnson & Johnson, what are the Government’s remaining options?
‘No change’ in risk profile with second blood clot case linked to AstraZeneca Two cases of clotting in 700,000 administered doses does not indicate an increased level of risk, experts have said.
Broader storage conditions for Pfizer vaccine bring GPs into the fold TGA-approved guideline changes have opened the possibility for general practices to take part in the rollout of the mRNA vaccine.
No legal risk for GPs administering AstraZeneca vaccine: Health Minister Greg Hunt has moved to reassure practitioners amid reports GPs stopped offering AstraZeneca to under-50s following recent ATAGI recommendations.
Changes to the vaccine rollout: What are the immediate impacts for GPs? Effects of Australia’s pivot from AstraZeneca to Pfizer for people under 50 are being felt as practices work to ease patient concerns.
ATAGI recommends major change to vaccine rollout Australian health authorities have recommended people under 50 receive the Pfizer vaccine rather than AstraZeneca.